All News

2020

August

Media Release / Aug 06, 2020

Novartis receives EC approval for new Xolair® indication to treat severe chronic rhinosinusitis with nasal polyps

Read More
Media Release / Aug 05, 2020

Novartis announces NEJM publication of Phase III ASCLEPIOS trials demonstrating superior efficacy of ofatumumab in patients with relapsing multiple sclerosis

Read More
Media Release / Aug 04, 2020

Novartis announces Kymriah® meets primary endpoint at interim analysis of pivotal study in follicular lymphoma

Read More
Media Release / Aug 03, 2020

Novartis Cosentyx® receives EU approval for first-line systemic treatment in pediatric psoriasis

Read More

July

Media Release / Jul 29, 2020

Novartis receives Piqray® approval in Europe – the first and only targeted medicine for HR+/HER2- advanced breast cancer with a PIK3CA mutation

Read More
Media Release / Jul 27, 2020

Sandoz announces plans for joint investment to help strengthen future of antibiotics manufacturing in Europe

Read More
Media Release / Jul 27, 2020

New Novartis analysis shows wet AMD patients achieved sustained fluid control faster with Beovu® versus aflibercept

Read More
Media Release / Jul 24, 2020

Novartis Adakveo® receives positive CHMP opinion for the prevention of recurrent vaso-occlusive crises in patients with sickle cell disease

Read More
Media Release / Jul 23, 2020

Novartis announces Phase III study of Jakavi® in chronic graft-versus-host disease met primary and key secondary endpoints

Read More
Media Release / Jul 21, 2020

Novartis delivered strong H1 performance. FY 2020 guidance confirmed at higher end for core operating income and lower end for sales.

Read More

Related Links

Novartis Annual Reporting Suite

Read and download the Annual Review, the Annual Report and Form 20-F, and the Novartis in Society ESG report.

Learn More